Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 26 March 2025 to Question 39290 on Coronavirus: Drugs, whether his Department has had recent discussions with the National Institute for Health and Care Excellence on the potential use of PEMGARDA to help protect clinically vulnerable people against covid-19 in emergency situations.

Ministers and Department officials have regular discussions with the National Institute for Health and Care Excellence (NICE) on a range of issues, including topics for new or updated guidance.

Pemivibart, also known under the brand name Pemgarda, for use in the prophylaxis of COVID-19, does not have a marketing authorisation in the United Kingdom issued by the Medicines and Healthcare products Regulatory Agency (MHRA). It is the responsibility of the company to apply to the MHRA for the relevant marketing authorisation. Should an application for it be received, the MHRA will consider the product for its benefits and risks in relation to quality, safety, and efficacy.

In England, NICE evaluates all newly licenced medicines to determine whether they represent a clinically and cost-effective use of National Health Service resources. If the manufacturer of Pemgarda seeks a licence from the MHRA, then NICE may consider it through its technology appraisal programme.